Sara C.
- Country
- Italy
- Department
- Neuropsichiatria dell'Infanzia e Adolescenza
Research Overview
- Evaluation of Long-Term Safety and Tolerability of Pimavanserin Tartrate in Pediatric Patients with Irritability Associated with Autism Spectrum Disorder
- Evaluation of Pitolisant Efficacy and Safety in Pediatric Autism Spectrum Disorders: A Randomized, Double-Blind, Placebo-Controlled Multicenter Study
- Evaluation of Intranasal Esketamine and Oral Midazolam for Rapid Symptom Reduction in Adolescent Major Depressive Disorder with Acute Suicidal Ideation
Data & Insights
Has run more than one trial at 19 of 60 partner sites.
Specializations
Neurodevelopmental Disorders
This investigator specializes in treating Autism Spectrum Disorders (ASD), with particular emphasis on addressing behavioral and social communication challenges in pediatric and adolescent populations.
- Social Communication Deficits
- Behavioral Management
- Pediatric ASD Care
The research focus includes therapeutic interventions targeting core ASD symptoms and associated behavioral manifestations.
Pediatric Psychiatry
Specialized expertise in treating irritability in children and adolescents with autism, exploring innovative therapeutic approaches for symptom management.
- Behavioral Interventions
- Long-term Safety Assessment
- Treatment Tolerability
Focuses on developing safe and effective long-term treatment strategies for young patients with ASD.
Therapeutic Innovation
Engages in the evaluation of novel therapeutic agents for ASD-related behavioral challenges, with emphasis on comprehensive symptom management approaches.
- Social Interaction Improvement
- Communication Enhancement
- Behavioral Symptom Control
Investigates treatment options aimed at improving quality of life for children and adolescents with ASD.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.